Kaleido BioSciences, Inc. develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/15/2019 11:08 PDT] Kaleido BioSciences, Inc. (OTC:KLDO), Down By 100.00% ($9.36) From $9.360 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [07/11/2019 07:47 PDT] KLDO Expected to Trade Down After Bearish Patterns Develop